Similar articles

• Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.

  Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank JK, Sever PS, Feder G; ASCOT. Gupta AK, et al. Am J Hypertens. 2010 Sep;23(9):1023-30. doi: 10.1038/ajh.2010.105. Epub 2010 Aug 19. Am J Hypertens. 2010. PMID: 20725056
• Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.

  Gosse P. Gosse P. Expert Rev Cardiovasc Ther. 2006 May;4(3):319-33. doi: 10.1586/14779072.4.3.319. Expert Rev Cardiovasc Ther. 2006. PMID: 16716093 Review.
• [Treating essential hypertension. Are beta blockers still first choice?].

  Rahn KH. Rahn KH. MMW Fortschr Med. 2007 May 3;149(18):43-5. MMW Fortschr Med. 2007. PMID: 17672414 German. No abstract available.
• Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

  Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Davis BR, et al. Circulation. 2006 May 9;113(18):2201-10. doi: 10.1161/CIRCULATIONAHA.105.544031. Epub 2006 May 1. Circulation. 2006. PMID: 16651474 Clinical Trial.
• Will ASCOT change the form of anti-hypertensive therapy?

  Bilous R. Bilous R. Diabet Med. 2006 Jan;23(1):13-4. doi: 10.1111/j.1464-5491.2006.01808.x. Diabet Med. 2006. PMID: 16409559 Review. No abstract available.